Corvus Pharmaceuticals, Inc. Class of Warrant or Right, Outstanding
Corvus Pharmaceuticals, Inc. (CRVS) had Class of Warrant or Right, Outstanding of 17.09 million shares as of 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Notes
us-gaap:ClassOfWarrantOrRightOutstanding · last filed 2024-11-12
- 2024-09-30: Class of Warrant or Right, Outstanding 17.09M shares.
- 2024-06-30: Class of Warrant or Right, Outstanding 17.09M shares.
- 2021-06-30: Class of Warrant or Right, Outstanding 1.46M shares.
- 2020-12-31: Class of Warrant or Right, Outstanding 1.46M shares.
| Period end | Class of Warrant or Right, Outstanding |
|---|---|
| 2024-09-30 | 17.09M shares 10-Q · filed 2024-11-12 |
| 2024-06-30 | 17.09M shares 10-Q · filed 2024-08-06 |
| 2021-06-30 | 1.46M shares 10-Q · filed 2021-08-02 |
| 2020-12-31 | 1.46M shares 10-K · filed 2023-03-28 |
| 2019-12-31 | 1.46M shares 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |